Mabwell will use the Brazil GMP win to accelerate denosumab filings across more markets.
For pharma watchers, this is a regulatory and commercialization signal: another market opens, and the company’s manufacturing credibility strengthens.
AI reasoning
For pharma watchers, this is a regulatory and commercialization signal: another market opens, and the company’s manufacturing credibility strengthens.
Curated summary
Mabwell said its subsidiary T-mab passed ANVISA’s GMP on-site inspection in Brazil for denosumab biosimilars 9MW0311 and 9MW0321. The result is its second PIC/S-member GMP certification after Jordan. Mabwell had already filed denosumab applications in eight countries and has marketing approval in Pakistan.
Source news
Mabwell clears another GMP hurdle for denosumab injections
The company says Brazilian inspectors passed its facility, adding to an earlier Jordan certification.
